BIO Europe, Basel 2023: Our thoughts
#BIO Europe is one of the most important Life Science events for people in the industry to attend. This year was no exception. ERS Senior Director,…
CRISPR-Made Greener Products and Processes in Industrial Biotechnology
Find out what role #CRISPR has to play in the new bio-industrial revolution in our latest article on #synbio and CRISPR’d #chemicals @GENbio https://www.genengnews.com/topics/bioprocessing/crispr-made-greener-products-and-processes-in-industrial-biotechnology/
Five things you need to know about using CRISPR/Cas9 commercially
Here are the 5 key facts you need to know, so you can secure the licenses that will protect your product and your company.
Welcome to the CRISPR Powerhouse – the power & flexibility of CRISPR/Cas9 for the antibody manufacturing pipeline.
In The Medicine Maker, ERS Genomics CEO, Eric Rhodes explores the power and flexibility of CRISPR/Cas9 for the antibody manufacturing pipeline, including for next-generation antibody-drug…
Foundational CRISPR/Cas9 gene editing patent granted to CVC in Canada
Dublin, Ireland, January 5, 2023: ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions and methods of using CRISPR/Cas9…
Crown Bioscience & ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
San Diego, USA and Dublin, Ireland 8 December 2022, Crown Bioscience, Inc and ERS Genomics Limited (‘ERS’) have signed a global license agreement for…
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
Dublin, Ireland, December 1, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license…
New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL
Dublin, Ireland, 17 November 2022: ERS Genomics Limited (‘ERS’) is pleased to announce ATLATL Innovation Centre (‘ATLATL’) as its non-exclusive agent for licensing ERS’ intellectual…
Gene editing Webinar: Navigating IP, deal-making and regulatory challenges
Tune in to listen to an engaging and insightful discussion hosted by Clarivate.
All articles loaded
No more articles to load